BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 12, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/9 cls
Celldex Therapeutics Inc. (NASDAQ:CLDX) Roth Capital Partners Joseph Pantginis Price target Buy 3% $3.90
Pantginis raised his target to $9 from $6 ahead of data from the Phase IIb EMERGE trial with CDX-011 in metastatic breast cancer at the American Society of Clinical Oncology meeting in June. Pantiginis also believes that the company's cash position will enable "fast paced pipeline progress." Celldex reported that it has sufficient cash to fund operations through 2014, with $53.3M as of Dec. 31, 2011, plus an...

Read the full 619 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >